<?xml version='1.0' encoding='utf-8'?>
<document id="26466656"><sentence text="Regimens for Patients Coinfected with Human Immunodeficiency Virus." /><sentence text="Hepatitis C virus (HCV) coinfection is prevalent in patients with human immunodeficiency virus (HIV) and has an accelerated disease course" /><sentence text=" Direct-acting antiviral (DAA) therapies that do not require interferon increase response rates to levels identical to those seen in HCV monoinfection" /><sentence text=" However, drug-drug interaction between antiretrovirals and HCV medication is the major consideration in deciding on the appropriate HCV therapeutic approach in patients with HIV" /><sentence text=" This article summarizes the currently available data with HCV DAAs in patients with HIV, and focuses on predicting and managing drug interaction to facilitate successful DAA-based HCV therapy in those with HIV" /><sentence text=" " /></document>